Recent Finacing
Recent Raise
Calypso Biotech develops IL‑15–targeted monoclonal antibodies, advancing lead candidate CALY‑002 in Phase 1 for gastrointestinal autoimmune indications; headquartered in Amsterdam with laboratories in Geneva.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Calypso Biotech.
